Graft-versus-host disease (GVHD) is an immune-mediated disease, which results from a multifaceted interaction amongst donor and recipient's adaptive immunity. GVHD is an induced indication and emerges post organ or tissue transplant. The probability of developing GVHD is higher in allogeneic transplant, a transplant where donor's organ/cell are used for transplantation compared with autologous transplant, a transplant where individual's cells have been used for transplant.
Covered in this report The report covers the present scenario and the growth prospects of the global graft vs host disease (GVHD) treatment market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs. The market is divided into the following segments based on geography: • Americas • APAC • EMEA To access full, click here: https://www.radiantinsights.com/research/global-graft-vs-host-disease-gvhd-treatment-market-2017-2021 Global Graft vs Host Disease (GVHD) Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Key vendors • Bristol-Myers Squibb • Novartis • Pfizer • F. Hoffmann-La Roche Other prominent vendors • Abbott • AbbVie • Allergan • Anterogen • Astellas Pharma • Athersys • Baxter • Caladrius • Cellular Biomedicine Group • Cipla • Eisai • Eli Lilly • GlaxoSmithKline • Glenmark • Helsinn Healthcare • Heron Therapeutics
0 Comments
Leave a Reply. |
Archives
December 2023
Categories |